# Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

> **NCT01791491** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 16 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** Belatacept

## Key facts

- **NCT ID:** NCT01791491
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-09
- **Primary completion:** 2016-12-06
- **Final completion:** 2016-12-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01791491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01791491, "Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01791491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*